Abstracts tagged "clinical trials and glucocorticoids"

Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting
Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Eli Miloslavsky¹, Raymond P. Naden², Johannes WJ Bijlsma³, Paul Brogan⁴, Sherwood Brown⁵, Paul Brunetta⁶, Frank Buttgereit⁷, Hyon K. Choi⁸, Jean-Francois Dicaire⁹, Jeffrey Gelfand¹⁰, Liam Heaney¹¹, Liz Lightstone¹², Leo Lu¹³, Dedee Murrell¹⁴, Michelle Petri¹⁵, James T. Rosenbaum¹⁶, Kenneth Saag¹⁷, Murray Urowitz¹⁸, Kevin L Winthrop¹⁹ and John H. Stone²⁰, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³ARC, Amsterdam, Netherlands, ⁴Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Psychiatry, UT Southwestern Medical Center, Dallas, TX, ⁶Genentech, Inc., South San Francisco, CA, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Pinnacle Inc., Quebec, QC, Canada, ¹⁰Neurology, University of California San Francisco, San Francisco, CA, ¹¹Department of Respiratory Medicine, Queen's University Belfast, Belfast, Ireland, ¹²Department of Medicine, Imperial College London, London, England, ¹³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Department of Dermatology, University of New South Wales, Sydney, Australia, ¹⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Oregon Health & Science University, Portland, OR, ¹⁷Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham School of Medicine, Birmingham, AL, ¹⁸Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁹Oregon Health and Sciences University, Portland, OR, ²⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity. New immunomodulatory agents offer the possibility of limiting GC exposure. To assess the comparative benefits of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].